The HEALEY ALS Platform Trial (ClinicalTrials.gov identifier: NCT04297683) is a multicentre, double-blind, placebo-controlled adaptive Phase 2/3 clinical trial conducted by the Sean M. Healey & AMG ...
LEXINGTON, Mass., March 09, 2026 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics to treat a ...
Hosted on MSN
First participant dosed with Neurizon’s lead drug candidate in landmark HEALEY ALS trial
First participant enrolled and dosed with Neurizon’s NUZ-001 in Regimen I of the HEALEY ALS Platform Trial for treatment of ALS Around 160 people living with ALS to be recruited into trial across ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results